Contact
searchSearch
HMP Global

Peripheral Arterial Disease Presentations

Dr Elizabeth Genovese
ISET 2026
When Do I Think of a Bypass? Reframing Revascularization Decisions in CLTI
02/11/2026
Elizabeth Genovese, MD, MS, FACS, RPVI
Dr Elizabeth Genovese asked a nuanced question regarding patients with CLTI: when should bypass be considered first—and why?
Dr Elizabeth Genovese asked a nuanced question regarding patients with CLTI: when should bypass be considered first—and why?
Dr Elizabeth Genovese asked a...
02/11/2026
Vascular Disease Management
John Rundback MD
ISET 2026
Vessel Preparation for Tibial Interventions: Why “Just PTA” Is Rarely Enough
02/11/2026
John H. Rundback, MD, FAHA, FSIR
Dr. John H. Rundback challenges the long-standing notion that plain balloon angioplasty alone is sufficient for tibial interventions in patients with chronic limb-threatening ischemia .
Dr. John H. Rundback challenges the long-standing notion that plain balloon angioplasty alone is sufficient for tibial interventions in patients with chronic limb-threatening ischemia .
Dr. John H. Rundback challenges...
02/11/2026
Vascular Disease Management
Dr Andrew Holden
ISET 2026
Bioresorbable Scaffolds in BTK Disease: Where We Are and Where We’re Headed
02/10/2026
Andrew Holden, MBChB
Dr Andrew Holden delivered a comprehensive and forward-looking overview of bioresorbable scaffold technology for BTK disease, with a particular focus on CLTI.
Dr Andrew Holden delivered a comprehensive and forward-looking overview of bioresorbable scaffold technology for BTK disease, with a particular focus on CLTI.
Dr Andrew Holden delivered a...
02/10/2026
Vascular Disease Management
Francesco Liistro, MD
LINC 2026
How to Optimize DCB Results in BTK Arteries: ‘Deep Drug Delivery Is Key!’
01/29/2026
Francesco Liistro, MD
Dr Francesco Liistro shares a pragmatic, mechanics-first approach to DCB therapy in BTK arteries.
Dr Francesco Liistro shares a pragmatic, mechanics-first approach to DCB therapy in BTK arteries.
Dr Francesco Liistro shares a...
01/29/2026
Vascular Disease Management
Dr Tatsuya Nakama
LINC 2026
First-Time Data Revealed From Three-Year PROSPECT MONSTER DCB Registry
01/29/2026
Tatsuya Nakama, MD
Dr Tatsuya Nakama discusses how device design, paclitaxel dose, and meticulous lesion preparation may shape long-term durability in everyday practice.
Dr Tatsuya Nakama discusses how device design, paclitaxel dose, and meticulous lesion preparation may shape long-term durability in everyday practice.
Dr Tatsuya Nakama discusses how...
01/29/2026
Vascular Disease Management
Dr Koen Deloose
LINC 2026
SEPARATE: Could Novel Impedance Sensor be the Best Way to Differentiate Clots in PAD?
01/28/2026
Koen Deloose, MD
An introduction to the SEPARATE feasibility clinical study of the Clotild Smart Guidewire System (Sensome) in peripheral artery disease was presented at LINC on Tuesday afternoon by Dr Koen Deloose.
An introduction to the SEPARATE feasibility clinical study of the Clotild Smart Guidewire System (Sensome) in peripheral artery disease was presented at LINC on Tuesday afternoon by Dr Koen Deloose.
An introduction to the SEPARATE...
01/28/2026
Vascular Disease Management
Dr Brodmann
AMP 2025
Transradial Access Shifts the Paradigm in Treating Chronic Limb-Threatening Ischemia
08/14/2025
Marianne Brodmann, MD
Marianne Brodmann, MD, delivered a detailed update on how she employs radial artery access to manage chronic limb-threatening ischemia.
Marianne Brodmann, MD, delivered a detailed update on how she employs radial artery access to manage chronic limb-threatening ischemia.
Marianne Brodmann, MD, delivered...
08/14/2025
Vascular Disease Management
Dr Pliagas
AMP 2025
How IVUS Changed My Intervention
08/14/2025
George Pliagas, MD, FACS, FRCSC
During Thursday’s “Diagnosis and Imaging in CLTI” session, George Pliagas, MD, FACS, FRCSC, shared how IVUS has reshaped his approach to treating peripheral vascular disease.
During Thursday’s “Diagnosis and Imaging in CLTI” session, George Pliagas, MD, FACS, FRCSC, shared how IVUS has reshaped his approach to treating peripheral vascular disease.
During Thursday’s “Diagnosis and...
08/14/2025
Vascular Disease Management
Dr Tokuda
AMP 2025
Atherectomy + DCB vs Stent-Based Repair for Severely Calcified Femoropopliteal Disease
08/13/2025
Takahiro Tokuda, MD
Vascular surgeon Dr. Takahiro Tokuda, from Nagoya Heart Center in Japan, outlines new evidence comparing 2 contemporary revascularization options for heavily calcified femoropopliteal lesions
Vascular surgeon Dr. Takahiro Tokuda, from Nagoya Heart Center in Japan, outlines new evidence comparing 2 contemporary revascularization options for heavily calcified femoropopliteal lesions
Vascular surgeon Dr. Takahiro...
08/13/2025
Vascular Disease Management
Dr Zeller
AMP 2025
WOUNDSinCLTI Trial Update: Pathogen-Driven Insights Into Limb Salvage in CLTI
08/13/2025
Thomas Zeller, MD, PhD
Thomas Zeller, MD, from the Universitaets-Herzzentrum Freiburg, Bad Krozingen, Germany, presented the inaugural findings from the WOUND infection and clinical outcomeS IN patients with Chronic Limb-Threatening Ischemia (WOUNDSinCLTI) study,
Thomas Zeller, MD, from the Universitaets-Herzzentrum Freiburg, Bad Krozingen, Germany, presented the inaugural findings from the WOUND infection and clinical outcomeS IN patients with Chronic Limb-Threatening Ischemia (WOUNDSinCLTI) study,
Thomas Zeller, MD, from the...
08/13/2025
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Endovascular Devices
Thrombolex, Inc. Secures $50 Million Series A Growth Financing to Advance Commercialization of its Innovative Pharmaco-Mechanical Lysis Technology (PML)
03/19/2026
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026...
03/19/2026
Vascular Disease Management
Neurovascular Care
Medtronic to Acquire Scientia Vascular, Marrying Access and Therapeutic Portfolios for Neurovascular Care
03/10/2026
Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'.
Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'.
Deal complements Medtronic's...
03/10/2026
Vascular Disease Management
VDM logo
Analysis
Artificial Intelligence Advances in Interventional Oncology: Year in Review
02/23/2026
Laura Simson, MA
02/23/2026
Vascular Disease Management
New Stroke Guidelines
New Guideline Expands Stroke Treatment for Adults, Offers First Pediatric Stroke Guidance
02/19/2026
Updated ischemic stroke recommendations from the American Stroke Association highlight how rapid diagnosis and imaging, extended time windows for stroke treatments and coordinated care involving emergency services, hospitals and health care...
Updated ischemic stroke recommendations from the American Stroke Association highlight how rapid diagnosis and imaging, extended time windows for stroke treatments and coordinated care involving emergency services, hospitals and health care...
Updated ischemic stroke...
02/19/2026
Vascular Disease Management
Radiation Safety
RAMPART Appoints Rob Williamson as Chief Revenue Officer
02/12/2026
BIRMINGHAM, Ala. — February 12, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced that Rob Williamson has been appointed Chief Revenue Officer (CRO), efective March...
BIRMINGHAM, Ala. — February 12, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced that Rob Williamson has been appointed Chief Revenue Officer (CRO), efective March...
BIRMINGHAM, Ala. — February 12,...
02/12/2026
Vascular Disease Management
The Salus and Tallahassee Memorial HealthCare teams celebrate after the first AeroShield case.
Radiation Protection Systems
Tallahassee Memorial HealthCare Advances Cath Lab Safety Through First-in-the-World Technology Adoption
02/10/2026
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Salus Scientific and Tallahassee...
02/10/2026
Cath Lab Digest
Embolic Device
Fluidx Embolic IDE Trial Results Accepted for Late-Breaking Presentation at the SIR Annual Meeting
02/10/2026
Fluidx Medical Technology, Inc. is a clinical-stage medical device company advancing its next-generation gel embolic technology.
Fluidx Medical Technology, Inc. is a clinical-stage medical device company advancing its next-generation gel embolic technology.
Fluidx Medical Technology, Inc....
02/10/2026
Vascular Disease Management
Thrombectomy
Avantec Vascular, a NIPRO Company, Announces FDA 510(k) Clearance of Thrombectomy System
02/10/2026
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
Sunnyvale, California...
02/10/2026
Cath Lab Digest
News
RAMPART Appoints Former Thoratec CEO Gary Burbach as Chairman of the Board
02/04/2026
BIRMINGHAM, Ala. — February 4, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the appointment of Gerhard (Gary) F. Burbach as Chairman of its Board of...
BIRMINGHAM, Ala. — February 4, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the appointment of Gerhard (Gary) F. Burbach as Chairman of its Board of...
BIRMINGHAM, Ala. — February 4,...
02/04/2026
Vascular Disease Management
Cardiovascular Scientific Forum
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
02/03/2026
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration...
02/03/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use